Laurent Malivert
Research Subjects
Laurent Malivert has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Pierre de Villartay
Université de Paris, Imagine Institute, Laboratory “Genome Dynamics in the Immune System”, INSERM UMR 1163, F-75015
9 shared publications - Patrick Revy
Laboratory of Genome Dynamics in Human Diseases, Equipe Labellisée Ligue 2026, INSERM UMR 1163, Imagine Institute
9 shared publications Alain Fischer
INSERM, Hôpital Necker-Enfants Malades, U768, Unité de Développement Normal et Pathologique du Système Immunitaire
3 shared publicationsJean-Paul Mornon
The ‡‡Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Unité d'Immunologie et d'Hématologie, Paris F-75015, France
3 shared publicationsPaola Rivera-Munoz
Laboratory of Genome Dynamics in the Immune System, INSERM U768, Paris, France
3 shared publicationsIsabelle Callebaut
The ‡‡Assistance Publique-Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Unité d'Immunologie et d'Hématologie, Paris F-75015, France
2 shared publications
Latest Publications
- Open Access
- 5 October 2014
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 21 (11) , 962-968
Structure and mechanism of action of the BRCA2 breast cancer tumor suppressor
Structural and biochemical analyses of full-length human BRCA2 reveal how it facilitates RAD51-mediated homologous recombination to repair DNA double-strand breaks. Mutations in BRCA2 increase susceptibility to breast, ovarian and prostate cancers. The product of human BRCA2, BRCA2 protein, has a key role in the repair of DNA double-strand breaks and interstrand cross-links by RAD51-mediated homologous recombination. Here, we present a biochemical and structural characterization of full-length (3,418 amino acid) BRCA2, alone and in complex with RAD51. We show that BRCA2 facilitates nucleation of RAD51 filaments at multiple sites on single-stranded DNA. Three-dimensional EM reconstructions revealed that BRCA2 exists as a dimer and that two oppositely oriented sets of RAD51 molecules bind the dimer. Single-stranded DNA binds along the long axis of BRCA2, such that only one set of RAD51 monomers can form a productive complex with DNA and establish filament formation. Our data define the molecular mechanism by which this tumor suppressor facilitates RAD51-mediated homologous-recombinational repair.
- 5 October 2014
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 21 (11) , 962-968
Open AccessStructure and mechanism of action of the BRCA2 breast cancer tumor suppressor
Structural and biochemical analyses of full-length human BRCA2 reveal how it facilitates RAD51-mediated homologous recombination to repair DNA double-strand breaks. Mutations in BRCA2 increase susceptibility to breast, ovarian and prostate cancers. The product of human BRCA2, BRCA2 protein, has a key role in the repair of DNA double-strand breaks and interstrand cross-links by RAD51-mediated homologous recombination. Here, we present a biochemical and structural characterization of full-length (3,418 amino acid) BRCA2, alone and in complex with RAD51. We show that BRCA2 facilitates nucleation of RAD51 filaments at multiple sites on single-stranded DNA. Three-dimensional EM reconstructions revealed that BRCA2 exists as a dimer and that two oppositely oriented sets of RAD51 molecules bind the dimer. Single-stranded DNA binds along the long axis of BRCA2, such that only one set of RAD51 monomers can form a productive complex with DNA and establish filament formation. Our data define the molecular mechanism by which this tumor suppressor facilitates RAD51-mediated homologous-recombinational repair.
- Open Access
- 1 February 2013
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 33 (4) , 701-711
Cernunnos Deficiency Reduces Thymocyte Life Span and Alters the T Cell Repertoire in Mice and Humans
Cernunnos is a DNA repair factor of the nonhomologous end-joining machinery. Its deficiency in humans causes radiosensitive severe combined immune deficiency (SCID) with microcephaly, characterized in part by a profound lymphopenia. In contrast to the human condition, the immune system of Cernunnos knockout (KO) mice is not overwhelmingly affected. In particular, Cernunnos is dispensable during V(D)J recombination in lymphoid cells. Nevertheless, the viability of thymocytes is reduced in Cernunnos KO mice, owing to the chronic activation of a P53-dependent DNA damage response. This translates into a qualitative alteration of the T cell repertoire to one in which the most distal Vα and Jα segments are missing. This results in the contraction of discrete T cell populations, such as invariant natural killer T (iNKT) and mucosa-associated invariant T (MAIT) cells, in both humans and mice.
- 1 February 2013
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 33 (4) , 701-711
Open AccessCernunnos Deficiency Reduces Thymocyte Life Span and Alters the T Cell Repertoire in Mice and Humans
Cernunnos is a DNA repair factor of the nonhomologous end-joining machinery. Its deficiency in humans causes radiosensitive severe combined immune deficiency (SCID) with microcephaly, characterized in part by a profound lymphopenia. In contrast to the human condition, the immune system of Cernunnos knockout (KO) mice is not overwhelmingly affected. In particular, Cernunnos is dispensable during V(D)J recombination in lymphoid cells. Nevertheless, the viability of thymocytes is reduced in Cernunnos KO mice, owing to the chronic activation of a P53-dependent DNA damage response. This translates into a qualitative alteration of the T cell repertoire to one in which the most distal Vα and Jα segments are missing. This results in the contraction of discrete T cell populations, such as invariant natural killer T (iNKT) and mucosa-associated invariant T (MAIT) cells, in both humans and mice.
- Open Access
- 1 August 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (34) , 26475-26483
Delineation of the Xrcc4-interacting Region in the Globular Head Domain of Cernunnos/XLF
- 1 August 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (34) , 26475-26483
Open AccessDelineation of the Xrcc4-interacting Region in the Globular Head Domain of Cernunnos/XLF
- 1 March 2009
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 29 (5) , 1116-1122
The C-Terminal Domain of Cernunnos/XLF Is Dispensable for DNA Repair In Vivo
The core nonhomologous end-joining DNA repair pathway is composed of seven factors: Ku70, Ku80, DNA-PKcs, Artemis, XRCC4 (X4), DNA ligase IV (L4), and Cernunnos/XLF (Cernunnos). Although Cernunnos and X4 are structurally related and participate in the same complex together with L4, they have distinct functions during DNA repair. L4 relies on X4 but not on Cernunnos for its stability, and L4 is required for optimal interaction of Cernunnos with X4. We demonstrate here, using in vitro-generated Cernunnos mutants and a series of functional assays in vivo, that the C-terminal region of Cernunnos is dispensable for its activity during DNA repair.
- 1 March 2009
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 29 (5) , 1116-1122
The C-Terminal Domain of Cernunnos/XLF Is Dispensable for DNA Repair In Vivo
The core nonhomologous end-joining DNA repair pathway is composed of seven factors: Ku70, Ku80, DNA-PKcs, Artemis, XRCC4 (X4), DNA ligase IV (L4), and Cernunnos/XLF (Cernunnos). Although Cernunnos and X4 are structurally related and participate in the same complex together with L4, they have distinct functions during DNA repair. L4 relies on X4 but not on Cernunnos for its stability, and L4 is required for optimal interaction of Cernunnos with X4. We demonstrate here, using in vitro-generated Cernunnos mutants and a series of functional assays in vivo, that the C-terminal region of Cernunnos is dispensable for its activity during DNA repair.
- 15 August 2008
- Published by American Society of Hematology in Blood
- Vol. 112 (4) , 1402-1412
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
The JAK2V617F mutation is frequently observed in classical myeloproliferative disorders, and disease progression is associated with a biallelic acquisition of the mutation occurring by mitotic recombination. In this study, we examined whether JAK2 activation could lead to increased homologous recombination (HR) and genetic instability. In a Ba/F3 cell line expressing the erythropoietin (EPO) receptor, mutant JAK2V617F and, to a lesser extent, wild-type (wt) JAK2 induced an increase in HR activity in the presence of EPO without modifying nonhomologous end-joining efficiency. Moreover, a marked augmentation in HR activity was found in CD34+-derived cells isolated from patients with polycythemia vera or primitive myelofibrosis compared with control samples. This increase was associated with a spontaneous RAD51 foci formation. As a result, sister chromatid exchange was 50% augmented in JAK2V617F Ba/F3 cells compared with JAK2wt cells. Moreover, JAK2 activation increased centrosome and ploidy abnormalities. Finally, in JAK2V617F Ba/F3 cells, we found a 100-fold and 10-fold increase in mutagenesis at the HPRT and Na/K ATPase loci, respectively. Together, this work highlights a new molecular mechanism for HR regulation mediated by JAK2 and more efficiently by JAK2V617F. Our study might provide some keys to understand how a single mutation can give rise to different pathologies.
- 15 August 2008
- Published by American Society of Hematology in Blood
- Vol. 112 (4) , 1402-1412
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
The JAK2V617F mutation is frequently observed in classical myeloproliferative disorders, and disease progression is associated with a biallelic acquisition of the mutation occurring by mitotic recombination. In this study, we examined whether JAK2 activation could lead to increased homologous recombination (HR) and genetic instability. In a Ba/F3 cell line expressing the erythropoietin (EPO) receptor, mutant JAK2V617F and, to a lesser extent, wild-type (wt) JAK2 induced an increase in HR activity in the presence of EPO without modifying nonhomologous end-joining efficiency. Moreover, a marked augmentation in HR activity was found in CD34+-derived cells isolated from patients with polycythemia vera or primitive myelofibrosis compared with control samples. This increase was associated with a spontaneous RAD51 foci formation. As a result, sister chromatid exchange was 50% augmented in JAK2V617F Ba/F3 cells compared with JAK2wt cells. Moreover, JAK2 activation increased centrosome and ploidy abnormalities. Finally, in JAK2V617F Ba/F3 cells, we found a 100-fold and 10-fold increase in mutagenesis at the HPRT and Na/K ATPase loci, respectively. Together, this work highlights a new molecular mechanism for HR regulation mediated by JAK2 and more efficiently by JAK2V617F. Our study might provide some keys to understand how a single mutation can give rise to different pathologies.
- 10 December 2007
- Published by Springer Nature in Oncogene
- Vol. 26 (56) , 7780-7791
V(D)J and immunoglobulin class switch recombinations: a paradigm to study the regulation of DNA end-joining
The immune system is the site of intense DNA damage/modification, which occur during the development and maturation of B and T lymphocytes. V(D)J recombination is initiated by the Rag1 and Rag2 proteins and the formation of a DNA double-strand break (DNA dsb). This DNA lesion is repaired through the use of the non-homologous end-joining (NHEJ) pathway, several factors of which have been identified through the survey of immunodeficient conditions in humans and mice. Upon antigenic recognition in secondary lymphoid organs, mature B cells further diversify their repertoire through class switch recombination (CSR). CSR is a region-specific rearrangement process triggered by the activation-induced cytidine deaminase factor and also proceeds through the introduction of DNA dsb. However, unlike V(D)J recombination, CSR does not rely strictly on NHEJ for the repair of the DNA lesion. Instead, CSR, but not V(D)J recombination, requires the major factors of the DNA damage response. V(D)J recombination and CSR thus represent an interesting paradigm to study the regulation among the various DNA repair pathways.
- 10 December 2007
- Published by Springer Nature in Oncogene
- Vol. 26 (56) , 7780-7791
V(D)J and immunoglobulin class switch recombinations: a paradigm to study the regulation of DNA end-joining
The immune system is the site of intense DNA damage/modification, which occur during the development and maturation of B and T lymphocytes. V(D)J recombination is initiated by the Rag1 and Rag2 proteins and the formation of a DNA double-strand break (DNA dsb). This DNA lesion is repaired through the use of the non-homologous end-joining (NHEJ) pathway, several factors of which have been identified through the survey of immunodeficient conditions in humans and mice. Upon antigenic recognition in secondary lymphoid organs, mature B cells further diversify their repertoire through class switch recombination (CSR). CSR is a region-specific rearrangement process triggered by the activation-induced cytidine deaminase factor and also proceeds through the introduction of DNA dsb. However, unlike V(D)J recombination, CSR does not rely strictly on NHEJ for the repair of the DNA lesion. Instead, CSR, but not V(D)J recombination, requires the major factors of the DNA damage response. V(D)J recombination and CSR thus represent an interesting paradigm to study the regulation among the various DNA repair pathways.
- Open Access
- 1 November 2007
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 282 (44) , 31937-31943
Interplay between Cernunnos-XLF and Nonhomologous End-joining Proteins at DNA Ends in the Cell
- 1 November 2007
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 282 (44) , 31937-31943
Open AccessInterplay between Cernunnos-XLF and Nonhomologous End-joining Proteins at DNA Ends in the Cell
- 1 November 2007
- Published by Wiley in European Journal of Immunology
- Vol. 37 (S1) , S71-S82
DNA repair and the immune system: From V(D)J recombination to aging lymphocytes
B and T lymphocytes are exposed to various genotoxic stresses during their life, which originate from programmed molecular mechanisms during their development and maturation or are secondary to cellular metabolism during acute phases of cell proliferation and activation during immune responses. How lymphocytes handle these multiple genomic assault has become a focus of interest over the years, perhaps beginning with the identification of the murine scid model in the early 80s when it was recognized that DNA repair deficiencies had profound consequences on the immune system. In this respect, the immune system represents an ideal model to study DNA damage responses (DDR) and the survey of immune deficiency conditions in humans or the development of specific animal models provided many major contributions in our understanding of the various biochemical pathways at play during DDR in general. Although the role of DNA repair in the early phases of B and T cell development has been analyzed thoroughly, the role of these functions in various aspects of the mature immune system (homeostasis, immunological memory, ageing) is less well understood. Lastly, the analysis of DNA repair in the immune system has provided many insights in the more general understanding of cancer.
- 1 November 2007
- Published by Wiley in European Journal of Immunology
- Vol. 37 (S1) , S71-S82
DNA repair and the immune system: From V(D)J recombination to aging lymphocytes
B and T lymphocytes are exposed to various genotoxic stresses during their life, which originate from programmed molecular mechanisms during their development and maturation or are secondary to cellular metabolism during acute phases of cell proliferation and activation during immune responses. How lymphocytes handle these multiple genomic assault has become a focus of interest over the years, perhaps beginning with the identification of the murine scid model in the early 80s when it was recognized that DNA repair deficiencies had profound consequences on the immune system. In this respect, the immune system represents an ideal model to study DNA damage responses (DDR) and the survey of immune deficiency conditions in humans or the development of specific animal models provided many major contributions in our understanding of the various biochemical pathways at play during DDR in general. Although the role of DNA repair in the early phases of B and T cell development has been analyzed thoroughly, the role of these functions in various aspects of the mature immune system (homeostasis, immunological memory, ageing) is less well understood. Lastly, the analysis of DNA repair in the immune system has provided many insights in the more general understanding of cancer.
- 1 December 2006
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 6 (6) , 416-420
Cernunnos-XLF, a recently identified non-homologous end-joining factor required for the development of the immune system
The analysis of immune deficiency conditions in humans has recently allowed the identification of a novel factor, Cernunnos, involved in DNA repair and required during the development of the immune system. The present review will focus on the information and new questions provided by the discovery of Cernunnos. The study of human immune deficiency conditions associated with defective DNA repair led to the recent identification of Cernunnos. Cernunnos is required for the ubiquitous DNA repair process mainly used in mammals, the non-homologous end-joining pathway. The analysis of Cernunnos defect conditions demonstrated the essential role of this novel factor during the development of the immune system. Cernunnos is homologous to the non-homologous end-joining factor, XRCC4, and is the genuine homologue of the yeast non-homologous end-joining factor, Nej1. These observations shed new light on the process underlying the last step of the non-homologous end-joining pathway, the DNA ends ligation. The elucidation of the molecular bases of rare inherited immune deficiencies associated with DNA repair defects provide considerable insights into our understanding of fundamental mechanisms such as the non-homologous end-joining ubiquitous DNA repair pathway.
- 1 December 2006
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 6 (6) , 416-420
Cernunnos-XLF, a recently identified non-homologous end-joining factor required for the development of the immune system
The analysis of immune deficiency conditions in humans has recently allowed the identification of a novel factor, Cernunnos, involved in DNA repair and required during the development of the immune system. The present review will focus on the information and new questions provided by the discovery of Cernunnos. The study of human immune deficiency conditions associated with defective DNA repair led to the recent identification of Cernunnos. Cernunnos is required for the ubiquitous DNA repair process mainly used in mammals, the non-homologous end-joining pathway. The analysis of Cernunnos defect conditions demonstrated the essential role of this novel factor during the development of the immune system. Cernunnos is homologous to the non-homologous end-joining factor, XRCC4, and is the genuine homologue of the yeast non-homologous end-joining factor, Nej1. These observations shed new light on the process underlying the last step of the non-homologous end-joining pathway, the DNA ends ligation. The elucidation of the molecular bases of rare inherited immune deficiencies associated with DNA repair defects provide considerable insights into our understanding of fundamental mechanisms such as the non-homologous end-joining ubiquitous DNA repair pathway.
- Open Access
- 1 May 2006
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 281 (20) , 13857-13860
Cernunnos Interacts with the XRCC4·DNA-ligase IV Complex and Is Homologous to the Yeast Nonhomologous End-joining Factor Nej1
- 1 May 2006
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 281 (20) , 13857-13860
Open AccessCernunnos Interacts with the XRCC4·DNA-ligase IV Complex and Is Homologous to the Yeast Nonhomologous End-joining Factor Nej1